U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma …
Apr 5, 2024 · Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial, with a 51% reduction in risk of disease progression or death and a well-established safety profile
FDA Approves First Cell-Based Gene Therapy for Adult Patients …
Mar 27, 2021 · The U.S. Food and Drug Administration approved Abecma (idecabtagene vicleucel), a cell-based gene therapy to treat adult patients with multiple myeloma who have not responded to, or whose...
Bristol Myers Squibb - Bristol Myers Squibb's Abecma® Becomes …
Dec 6, 2023 · Abecma is the first-in-class BCMA-directed CAR T cell immunotherapy. Abecma recognizes and binds to BCMA on the surface of multiple myeloma cells, which leads to the proliferation of CAR T cells and cytokine release, resulting in the dissolution and death of BCMA-expressing cells.
Bristol Myers Squibb - Bristol Myers Squibb’s Abecma …
Mar 20, 2024 · Bristol Myers Squibb assumes sole responsibility for Abecma drug product manufacturing and commercialization outside of the U.S. The companies’ broad clinical development program for Abecma includes ongoing and planned clinical studies (KarMMa-2, KarMMa-9) for patients with multiple myeloma.
Citing enrollment challenges, Bristol Myers and 2seventy scrap Abecma …
Sep 25, 2024 · Bristol Myers Squibb’s struggling CAR-T therapy Abecma has hit a major setback. Bristol and its partner 2seventy bio have decided to pull the plug on the phase 3 KarMMa-9 trial.
FDA calls for adcomm on BMS's Abecma in earlier treatment line
Nov 20, 2023 · BMS's effort to gain approval for Abecma in an earlier line of treatment—set for an FDA decision on Dec. 16—will be pushed back pending an FDA adcomm.
2seventy bio Inc (TSVT) Q3 2024 Earnings Call Highlights: Strong Abecma …
2 days ago · Abecma US Revenue: $77 million in the third quarter, reflecting a 42% growth over the prior quarter. Projected Abecma US Revenue for 2024: Approximately $240 to $250 million.
FDA ODAC Review of Abecma | Int'l Myeloma Foundation
On Friday, March 15, the FDA Oncologic Drugs Advisory Committee (ODAC) meeting rules on the benefit-risk assessment for Bristol-Myers Squibb and 2seventy bio’s Abecma (idecabtagene vicleucel).
Bristol Myers Squibb : Abecma® Becomes First CAR T Approved …
Dec 6, 2023 · Abecma is the first-in-class BCMA-directed CAR T cell immunotherapy. Abecma recognizes and binds to BCMA on the surface of multiple myeloma cells, which leads to the proliferation of CAR T cells and cytokine release, resulting in the dissolution and death of BCMA-expressing cells.
FDA approves BMS' multiple myeloma CAR-T Abecma
Nov 5, 2024 · The FDA has approved Bristol-Myers Squibb’s Abecma (idecabtagene vicleucel) for multiple myeloma, the first cell therapy to treat the disease.